GlassScriptPhysician profile
Kahley Wampler
NPI 1053074831
$1,102.57
in general payments reported to CMS, 2019-2025
17 companies · $83.29 in 2025
The $83.29 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $735 · 2024: $124 · 2025: $83.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $175.18 | 2023 | Aristada, Lybalvi, Vivitrol |
| Idorsia Pharmaceuticals US INC | $152.95 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $136.28 | 2022-2023 | Hetlioz, Fanapt |
| Novo Nordisk INC | $99.26 | 2024-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $86.91 | 2022-2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.69 | 2023 | Caplyta |
| Abbvie INC. | $78.07 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.05 | 2023 | Trintellix |
| Lundbeck LLC | $48.45 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $45.14 | 2023-2024 | Ingrezza |
| Heron Therapeutics, INC. | $34.45 | 2024 | Zynrelef |
| Tempus Ai, INC | $23.79 | 2024 | |
| Lemaitre Vascular, INC. | $19.21 | 2024 | Xenosure Biologic Patch |
| Sunovion Pharmaceuticals INC. | $18.91 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.05 | 2023 | Abilify Maintena, Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $14.62 | 2023 | Qelbree |
| Currax Pharmaceuticals LLC | $14.56 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kahley Wampler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.